MRNA-1345 is a mrna vaccine commercialized by Moderna, with a leading Pre-Registration program in Respiratory Syncytial Virus (RSV) Infections. According to Globaldata, it is involved in 11 clinical trials, of which 1 was completed, and 10 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of MRNA-1345’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for MRNA-1345 is expected to reach an annual total of $1.36 bn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
MRNA-1345 Overview
mRNA-1345 is under development for the prevention of respiratory syncytial virus (RSV) infection in young children and adults. It comprises of lipid nanoparticles encapsulated mRNAs encoding for a prefusion F glycoprotein. The therapeutic is developed based on lipid nanoparticles (LNP) technology and mRNA expression platform. It is administered through parenteral and intramuscular route.
Moderna Overview
Moderna is a biotechnology company that focuses on the development of messenger RNA (mRNA) therapeutics and vaccines. The company develops and discovers drugs that produce proteins or antibodies inside patient cells. Its pipeline includes various drug modalities such as prophylactic vaccines, therapeutic vaccines, intratumoral immuno-oncology, localized therapeutics, and liver intracellular. Moderna through its mRNA therapeutics platform develops and produces human proteins, antibodies, and novel proteins, which help in preventing, treating, and curing diseases. It also develops therapeutics in the areas of infectious disease, rare liver disease, immuno-oncology, and cardiovascular disease. Moderna Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of MRNA-1345’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.